MyMelanoma Update with Professor Mark Middleton, Professor of Experimental Cancer Medicine

Mark is Co-Director of Oxford Cancer and Head of Oncology at the University of Oxford, where he founded the Early Phase Clinical Trials Unit. His clinical and research interests are in new drug development, the treatment of melanoma and upper GI tumours and the early detection of new and relapsing cancers. He has been Chief or Principal Investigator on greater than 100 trials and closely involved in the development of new therapies including DNA repair, immune checkpoint and kinase inhibitors, bi-specific T-cell engagers and oncolytic viruses. Mark trained in Medicine at the Universities of Cambridge and Oxford, and in Oncology at the Christie Hospital and University of Manchester.